{"id":48629,"date":"2025-11-20T14:27:37","date_gmt":"2025-11-20T06:27:37","guid":{"rendered":"https:\/\/flcube.com\/?p=48629"},"modified":"2025-11-20T14:27:38","modified_gmt":"2025-11-20T06:27:38","slug":"lynks-lnk01004-pan-jak-inhibitor-shows-easi-75-win-in-phase-2-atopic-dermatitis-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48629","title":{"rendered":"Lynk&#8217;s LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial"},"content":{"rendered":"\n<p><strong>Lynk Pharmaceuticals Co., Ltd.<\/strong> announced positive Phase\u202fII data for its self\u2011developed Class\u202f1 innovative drug <strong>LNK01004<\/strong>, a skin\u2011restricted pan\u2011JAK inhibitor ointment, demonstrating statistically significant EASI\u201175 response rates in adult atopic dermatitis (AD) patients, with prominent efficacy in moderate\u2011to\u2011severe cases and minimal systemic exposure.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trial-milestone\">Trial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>LNK01004 ointment (skin\u2011restricted pan\u2011JAK inhibitor)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Lynk Pharmaceuticals Co., Ltd.<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Phase\u202fII (randomized, double\u2011blind, vehicle\u2011controlled, parallel\u2011group)<\/td><\/tr><tr><td><strong>Patients<\/strong><\/td><td>75 adult AD subjects randomized 1:1:1<\/td><\/tr><tr><td><strong>Dosing<\/strong><\/td><td>0.3% ointment, 1.0% ointment, or vehicle, applied BID for 8\u202fweeks<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>EASI\u201175 response rate at Week\u202f8<\/td><\/tr><tr><td><strong>Key Result<\/strong><\/td><td>Both dose groups achieved higher EASI\u201175 vs vehicle, advantage amplified in BSA\u226510% subgroup<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Phase\u202fIII initiation planned for H2\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> First\u2011in\u2011class skin\u2011restricted pan\u2011JAK inhibitor designed for topical administration<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Selectively inhibits JAK signaling within skin tissue, minimizing systemic circulation<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Lipophilic formulation achieves high local concentration while maintaining low systemic exposure\u2014several hundred\u2011fold below whole\u2011blood IC50<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> LNK01004 is Lynk\u2019s lead dermatology asset; focused on AD with potential expansion to other inflammatory skin diseases<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-summary\">Clinical Evidence Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>0.3% LNK01004<\/th><th>1.0% LNK01004<\/th><th>Vehicle<\/th><\/tr><\/thead><tbody><tr><td><strong>EASI\u201175 (BSA\u226510%)<\/strong><\/td><td><strong>61.1%<\/strong><\/td><td>46.2%<\/td><td>20%<\/td><\/tr><tr><td><strong>vIGA\u2011AD 0\/1 (BSA\u226510%)<\/strong><\/td><td><strong>44.4%<\/strong><\/td><td>38.5%<\/td><td>10%<\/td><\/tr><tr><td><strong>EASI\u201175 (BSA\u226520%)<\/strong><\/td><td>Prominent advantage vs vehicle, underscoring potential in moderate\u2011to\u2011severe AD<\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>All p\u2011values &lt;0.05 for active arms vs vehicle in BSA\u226510% cohort.<\/em><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-safety-profile\">Safety Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Systemic Exposure:<\/strong> Mean Cmax 0.0628\u202fng\/mL (0.3%) and 0.1499\u202fng\/mL (1.0%), >100\u2011fold below human whole\u2011blood IC50<\/li>\n\n\n\n<li><strong>Tolerability:<\/strong> All treatment\u2011related adverse events (TRAEs) were mild or moderate (Grade\u202f1\/2)<\/li>\n\n\n\n<li><strong>Serious AEs:<\/strong> No drug\u2011related serious adverse events (SAEs) observed<\/li>\n\n\n\n<li><strong>Consistency:<\/strong> Safety profile aligns with earlier\u2011stage studies, supporting favorable risk\u2011benefit<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China AD Market:<\/strong> ~25\u202fmillion AD patients; moderate\u2011to\u2011severe segment represents 30\u201140% of cases with limited topical options beyond corticosteroids and calcineurin inhibitors<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Oral JAK inhibitors (e.g., upadacitinib) carry systemic safety warnings; LNK01004\u2019s skin\u2011restricted profile offers a <strong>topical alternative with JAK\u2011class efficacy<\/strong> and minimal systemic risk<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts project China peak sales potential of <strong>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> (~US$110\u2011165\u202fmillion) by 2032, assuming 15\u201120% share of moderate\u2011to\u2011severe AD topical market<\/li>\n\n\n\n<li><strong>Regulatory Path:<\/strong> Phase\u202fII success positions LNK01004 for <strong>Breakthrough Therapy Designation<\/strong> with NMPA, accelerating review timeline<\/li>\n\n\n\n<li><strong>Next Catalysts:<\/strong> Phase\u202fIII protocol agreement expected Q1\u202f2026; data readout targeted for 2027, contingent on enrollment speed<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding LNK01004\u2019s clinical development, regulatory pathway, and commercial prospects. Actual results may differ materially due to risks including Phase\u202fIII execution, competitive dynamics, and market adoption of topical JAK inhibitors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lynk Pharmaceuticals Co., Ltd. announced positive Phase\u202fII data for its self\u2011developed Class\u202f1 innovative drug LNK01004,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48693,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,17,1351],"class_list":["post-48629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-results","tag-lynk-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lynk&#039;s LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced positive Phase\u202fII data for its self\u2011developed Class\u202f1 innovative drug LNK01004, a skin\u2011restricted pan\u2011JAK inhibitor ointment, demonstrating statistically significant EASI\u201175 response rates in adult atopic dermatitis (AD) patients, with prominent efficacy in moderate\u2011to\u2011severe cases and minimal systemic exposure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48629\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lynk&#039;s LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial\" \/>\n<meta property=\"og:description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced positive Phase\u202fII data for its self\u2011developed Class\u202f1 innovative drug LNK01004, a skin\u2011restricted pan\u2011JAK inhibitor ointment, demonstrating statistically significant EASI\u201175 response rates in adult atopic dermatitis (AD) patients, with prominent efficacy in moderate\u2011to\u2011severe cases and minimal systemic exposure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48629\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-20T06:27:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-20T06:27:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1902-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lynk&#8217;s LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial\",\"datePublished\":\"2025-11-20T06:27:37+00:00\",\"dateModified\":\"2025-11-20T06:27:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629\"},\"wordCount\":438,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1902-1.webp\",\"keywords\":[\"Auto-immune\",\"Clinical trial results\",\"Lynk Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48629#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48629\",\"name\":\"Lynk's LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1902-1.webp\",\"datePublished\":\"2025-11-20T06:27:37+00:00\",\"dateModified\":\"2025-11-20T06:27:38+00:00\",\"description\":\"Lynk Pharmaceuticals Co., Ltd. announced positive Phase\u202fII data for its self\u2011developed Class\u202f1 innovative drug LNK01004, a skin\u2011restricted pan\u2011JAK inhibitor ointment, demonstrating statistically significant EASI\u201175 response rates in adult atopic dermatitis (AD) patients, with prominent efficacy in moderate\u2011to\u2011severe cases and minimal systemic exposure.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48629\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1902-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1902-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lynk's LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48629#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lynk&#8217;s LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lynk's LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Lynk Pharmaceuticals Co., Ltd. announced positive Phase\u202fII data for its self\u2011developed Class\u202f1 innovative drug LNK01004, a skin\u2011restricted pan\u2011JAK inhibitor ointment, demonstrating statistically significant EASI\u201175 response rates in adult atopic dermatitis (AD) patients, with prominent efficacy in moderate\u2011to\u2011severe cases and minimal systemic exposure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48629","og_locale":"en_US","og_type":"article","og_title":"Lynk's LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial","og_description":"Lynk Pharmaceuticals Co., Ltd. announced positive Phase\u202fII data for its self\u2011developed Class\u202f1 innovative drug LNK01004, a skin\u2011restricted pan\u2011JAK inhibitor ointment, demonstrating statistically significant EASI\u201175 response rates in adult atopic dermatitis (AD) patients, with prominent efficacy in moderate\u2011to\u2011severe cases and minimal systemic exposure.","og_url":"https:\/\/flcube.com\/?p=48629","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-20T06:27:37+00:00","article_modified_time":"2025-11-20T06:27:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1902-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48629#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48629"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lynk&#8217;s LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial","datePublished":"2025-11-20T06:27:37+00:00","dateModified":"2025-11-20T06:27:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48629"},"wordCount":438,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48629#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1902-1.webp","keywords":["Auto-immune","Clinical trial results","Lynk Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48629#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48629","url":"https:\/\/flcube.com\/?p=48629","name":"Lynk's LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48629#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48629#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1902-1.webp","datePublished":"2025-11-20T06:27:37+00:00","dateModified":"2025-11-20T06:27:38+00:00","description":"Lynk Pharmaceuticals Co., Ltd. announced positive Phase\u202fII data for its self\u2011developed Class\u202f1 innovative drug LNK01004, a skin\u2011restricted pan\u2011JAK inhibitor ointment, demonstrating statistically significant EASI\u201175 response rates in adult atopic dermatitis (AD) patients, with prominent efficacy in moderate\u2011to\u2011severe cases and minimal systemic exposure.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48629#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48629"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48629#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1902-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1902-1.webp","width":1080,"height":608,"caption":"Lynk's LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48629#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lynk&#8217;s LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1902-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48629"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48629\/revisions"}],"predecessor-version":[{"id":48692,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48629\/revisions\/48692"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48693"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}